Resetting the T Cell Repertoire in Prostate Cancer Bearing Host
Annual rept. 5 Feb 2007-4 Feb 2008
MICHIGAN UNIV ANN ARBOR
Pagination or Media Count:
This is the first annual report on the grant Resetting the T cell repertoire in prostate cancer bearing host. A major obstacle to effective anti-tumor immune response is immune tolerance to tumor antigens, mostly caused by the defective cancer-reactive T-cell repertoire and increased immune suppression by regulatory T cells. We proposed to reset the immune system of cancer-bearing host by rescuing cancer-reactive T cells and by eliminating the generation and survival of Treg. 1. To rescue cancer-reactive T cells by preventing clonal deletion of tumor-reactive T cells in the thymus. 2. To block the Treg production using anti-B7 antibodies and to optimize the immunotherapy of prostate cancer using antibodies and fusion proteins. In the past funding period, we have submitted two papers that summarized our results from specific aim 2 in modulating Treg production in anti-tumor immunity and related subject on the role of costimulatory molecule B7 on NKT cell development. We are in the process to finish the data analyses for specific aim 1.
- Medicine and Medical Research